Bionest

Analysts’ Predictions on Top 10 Best Selling Drugs in 2024 — And Our Take

Market analyst firm Evaluate released their annual report, “EvaluatePharma World Preview 2018: Outlook to 2024,” last month. The report predicts that worldwide prescription drug sales will grow to over $1.2 trillion over the next six years. Novartis is projected to be 2024’s leading prescription drug company with $53.2 billion in overall sales, followed by Pfizer...

Bionest

A New ‘Neulasta’: First Biosimilar Version Gains FDA Approval

In early June, the U.S. Food and Drug Administration (FDA) approved the first biosimilar version of Amgen’s Neulasta (pegfilgrastim), a biologic that is used to reduce the chances of infection in cancer patients whose immune system have been suppressed by chemotherapy. The new biosimilar, developed by Mylan and Biocon, is expected to launch as Fulphila...

Bionest

Precision Medicine and NGS Cancer Panels — ASCO Round-Up Part Two

As we wrote in our last post, precision medicine in oncology was the big theme of this year’s ASCO meeting. One of the key advances that has made possible this focus on treating cancer based on particular biomarkers expressed by a patient’s tumors, has been the advent of Next-Generation Sequencing (NGS)-based analysis of tumor DNA....

Bionest

A Few Takeaways from ASCO 2018 — Part One

Precision medicine was an important theme of ASCO 2018 — the annual meeting of the American Society of Clinical Oncology — with this year’s meeting subtitled as “Delivering Discoveries, Expanding the Reach of Precision Medicine.”  This theme was reflected not only in discussions around molecular profiling of patients, but also by the ever-increasing focus on...